Nasdaq · Healthcare
Cryoport, Inc. (CYRX)
As-reported financials and recent SEC filings for Cryoport, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$176.2M
Net income
$78.3M
Net margin
44.4%
Diluted EPS
$1.40
ROE
15.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $176.2M | $156.8M | $168.7M | $237.3M | $222.6M |
| Gross profit | $83.1M | $69.7M | $75.3M | $103.9M | $96.6M |
| Operating income | $-36.8M | $-121.7M | $-100.5M | $-31.9M | $-17.8M |
| Net income | $78.3M | $-114.8M | $-99.6M | $-37.3M | $-275.5M |
| Diluted EPS | $1.40 | $-2.49 | $-2.21 | $-0.93 | $-6.18 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
15-12G2026-06-22
View on EDGAR →S-82026-06-22
View on EDGAR →42026-06-12
View on EDGAR →1442026-06-11
View on EDGAR →1442026-06-10
View on EDGAR →8-K2026-06-09
View on EDGAR →42026-06-09
View on EDGAR →1442026-06-08
View on EDGAR →Largest Healthcare peers
Go deeper on CYRX
Search Cryoport, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.